The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Myszkowski Kenneth Allen since 2010.
This trader's CIK number is 1486672.
At the time of last reporting, Myszkowski Kenneth Allen was the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc.. (stock ticker symbol ARWR).
Also see all insider trading activities at Arrowhead Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ARWR | 0 | $0 | 45,167 | $894,861 | 0 | $0 |
| 2024 | ARWR | 0 | $0 | 56,104 | $1,969,420 | 0 | $0 |
| 2023 | ARWR | 0 | $0 | 15,000 | $543,000 | 0 | $0 |
| 2022 | ARWR | 0 | $0 | 70,625 | $3,721,200 | 0 | $0 |
| 2021 | ARWR | 0 | $0 | 43,663 | $3,252,642 | 0 | $0 |
| 2020 | ARWR | 0 | $0 | 132,984 | $7,801,320 | 106,022 | $985,023 |
| 2019 | ARWR | 0 | $0 | 163,163 | $3,579,559 | 93,533 | $572,173 |
| 2018 | ARWR | 0 | $0 | 99,000 | $1,471,925 | 99,000 | $274,361 |
| 2016 | ARWR | 0 | $0 | 43,347 | $303,117 | 20,000 | $40,198 |
| 2014 | ARWR | 0 | $0 | 56,000 | $861,168 | 56,000 | $275,959 |
| 2010 | ARWR | 15,000 | $13,350 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-06 | ARWR | Sale | 27,167 | 19.89 | 540,351 |
| 2025-01-07 | ARWR | Sale | 18,000 | 19.70 | 354,510 |
| 2024-03-06 | ARWR | Sale | 40,000 | 35.19 | 1,407,600 |
| 2024-01-05 | ARWR | Sale | 16,104 | 34.89 | 561,820 |
| 2023-06-27 | ARWR | Sale | 15,000 | 36.20 | 543,000 |
| 2022-12-29 | ARWR | Sale | 30,625 | 40.00 | 1,225,000 |
| 2022-01-05 | ARWR | Sale | 40,000 | 62.41 | 2,496,200 |
| 2021-01-11 | ARWR | Sale | 11,597 | 81.02 | 939,588 |
| 2021-01-12 | ARWR | Sale | 1,441 | 81.00 | 116,721 |
| 2021-01-06 | ARWR | Sale | 30,625 | 71.72 | 2,196,333 |
| 2020-11-09 | ARWR | Sale | 43,505 | 69.45 | 3,021,422 |
| 2020-11-09 | ARWR | Option Ex | 43,505 | 14.54 | 632,562 |
| 2020-10-20 | ARWR | Option Ex | 29,166 | 6.15 | 179,370 |
| 2020-10-20 | ARWR | Sale | 29,166 | 54.04 | 1,576,130 |
| 2020-01-21 | ARWR | Option Ex | 33,351 | 5.19 | 173,091 |
| 2020-01-21 | ARWR | Sale | 40,313 | 49.55 | 1,997,428 |
| 2020-01-06 | ARWR | Sale | 20,000 | 60.32 | 1,206,340 |
| 2019-11-05 | ARWR | Option Ex | 12,649 | 5.19 | 65,648 |
| 2019-11-01 | ARWR | Option Ex | 37,884 | 7.75 | 293,601 |
| 2019-11-01 | ARWR | Sale | 37,884 | 40.88 | 1,548,887 |
| 2019-05-31 | ARWR | Option Ex | 35,000 | 4.89 | 171,324 |
| 2019-05-21 | ARWR | Sale | 27,071 | 22.00 | 595,562 |
| 2019-02-19 | ARWR | Option Ex | 8,000 | 5.20 | 41,600 |
| 2019-02-19 | ARWR | Sale | 8,000 | 18.00 | 144,000 |
| 2019-01-17 | ARWR | Sale | 81,875 | 14.55 | 1,191,281 |
| 2019-01-02 | ARWR | Sale | 8,333 | 11.98 | 99,829 |
| 2018-09-06 | ARWR | Sale | 45,000 | 19.50 | 877,725 |
| 2018-09-06 | ARWR | Option Ex | 45,000 | 3.69 | 165,825 |
| 2018-06-19 | ARWR | Option Ex | 20,000 | 2.01 | 40,199 |
| 2018-06-19 | ARWR | Sale | 20,000 | 14.01 | 280,200 |
| 2018-05-30 | ARWR | Option Ex | 1,400 | 2.01 | 2,813 |
| 2018-05-31 | ARWR | Option Ex | 12,600 | 2.01 | 25,325 |
| 2018-05-30 | ARWR | Sale | 1,400 | 11.00 | 15,400 |
| 2018-05-31 | ARWR | Sale | 12,600 | 11.00 | 138,600 |
| 2018-03-27 | ARWR | Option Ex | 20,000 | 2.01 | 40,199 |
| 2018-03-27 | ARWR | Sale | 20,000 | 8.00 | 160,000 |
| 2016-08-23 | ARWR | Sale | 6,900 | 8.00 | 55,200 |
| 2016-08-22 | ARWR | Option Ex | 13,100 | 2.01 | 26,330 |
| 2016-08-23 | ARWR | Option Ex | 6,900 | 2.01 | 13,868 |
| 2016-08-22 | ARWR | Sale | 13,100 | 8.00 | 104,800 |
| 2015-12-30 | ARWR | Sale | 23,347 | 6.13 | 143,117 |
| 2014-08-15 | ARWR | Option Ex | 40,000 | 6.09 | 243,800 |
| 2014-08-15 | ARWR | Sale | 40,000 | 14.02 | 560,880 |
| 2014-02-12 | ARWR | Sale | 16,000 | 18.77 | 300,288 |
| 2014-02-12 | ARWR | Option Ex | 16,000 | 2.01 | 32,159 |
| 2010-08-27 | ARWR | Buy | 15,000 | .89 | 13,350 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Myszkowski Kenneth Allen (Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.